DMA4-H228
DC60856
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →Open full Formulation & Performance →
Literature evidence · DC67602
Formulation & Performance
The evidence below is specifically attributed to E12LA6B6O3 in WO2024198497A1. Particle properties, cellular reporter expression, mouse reporter studies and tumor growth are kept separate. Clinical platform results are not assigned to this catalog structure.
The patent identifier is E12LA6B6O3, using the letter O before the final 3. Example 2 and the catalog structure are consistent with C51H97NO9 and average molecular weight 868.335. Absolute tail stereochemistry is not assigned. The ILB-3132 alias-to-structure link remains unconfirmed in primary sources.
Formulation components and molecular-weight conversion
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| E12LA6B6O3 (catalog structure) | DC67602 | 868.335 | Not assigned | Not calculable from disclosed data |
| DSPC | DC57005 | 790.15 | Not assigned | Not calculable from disclosed data |
| Cholesterol | DCD-041 | 386.65 | Not assigned | Not calculable from disclosed data |
| DMG-PEG2000 | DC40169 | 2507 | Not assigned | Not calculable from disclosed data |
The patent uses the named four-component system for reporter and OVA-mRNA experiments. The separate Example 40 series contains an unresolved discrepancy between the narrative and Table 4. The affected formulations must not be represented as a single verified recipe or used as a default calculator input.
Component mass calculator
Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.
| Component | MW | Molar ratio | Mass (mg) | Mass % |
|---|---|---|---|---|
| E12LA6B6O3 (catalog structure) | ||||
| DSPC | ||||
| Cholesterol | ||||
| DMG-PEG2000 |
Identity and evidence boundaries
| Item | Finding | Implication |
|---|---|---|
| Patent compound | E12LA6B6O3, Example 2 | Use the patent identifier beside patent-derived results |
| Catalog identity | Formula C51H97NO9; molecular weight 868.335 | Matches the catalog structure; not proof of clinical-platform identity |
| Sponsor disclosure | MagicRNA describes ILB-3132 as a proprietary core lipid | The reviewed sponsor text does not disclose a structure that proves the E12LA6B6O3 alias |
| Clinical report | A 2025 NEJM letter reports a complete in vivo CAR-T platform | Its outcomes cannot establish clinical performance of this catalog structure |
WO2024198497A1, Example 2; MagicRNA ASGCT announcement (April 30, 2025); Wang et al., NEJM 2025, DOI 10.1056/NEJMc2509522. The clinical supplementary appendix could not be retrieved for structure verification.
Measured particle attributes
| Parameter | LNP-7 result | Source |
|---|---|---|
| Average diameter | 75 nm | Table 1 |
| PDI | 0.08 | Table 1 |
| Encapsulation efficiency | 98.26% | Table 1 |
| Apparent pKa | Not established in the reviewed source | Do not infer from other lipids |
WO2024198497A1, Example 36, Table 1, PDF p42 / printed p41. These are formulation-specific values, not batch specifications for the free lipid.
Cellular reporter-expression evidence
| Assay | Reported signal | Interpretation |
|---|---|---|
| Primary mouse BMDCs, LNP-7 row | 1.8 × 10^5 | Table 2 reports reporter intensity; calibrated units are unstated |
| DLin-MC3 comparator | 4.1 × 10^4 | Within-table comparator; not an absolute transfection percentage |
| SM-102 comparator | 1.0 × 10^5 | Within-table comparator |
| Duplicate identifier | Another Table 2 row labels LNP-11 as E12LA6B6O3 with a different result | Do not combine the two rows or select the higher value as confirmed E12LA6B6O3 performance |
Example 37, Table 2, PDF pp44–45 / printed pp43–44. Row identity inconsistency limits exact quantitative attribution.
Mouse reporter-expression evidence
| Study | Reported result | Boundary |
|---|---|---|
| Intramuscular reporter study | E12LA6B6O3 signal: 2.2 × 10^9 | Table 3, row 4; reported intensity without calibrated units |
| Comparators in the same table | DLin-MC3: 7.6 × 10^8; SM-102: 1.4 × 10^9 | Reporter-expression comparisons only; not clinical efficacy |
| Separate intravenous series | Example 40 reports changes in expression across phospholipid variants | The narrative specifies 42.5% amino lipid whereas Table 4 prints 40%; do not combine this series with the intramuscular results |
Example 38, Table 3, PDF pp45–46; Example 40, Tables 4–5, PDF pp47–48. Different routes and particle compositions are separate experiments.
Tumor-model findings and endpoint correction
| Evidence | Supported interpretation | Not supported |
|---|---|---|
| B16-OVA mouse study | Figure 2 shows slower tumor growth for the E12LA6B6O3 formulation than for MC3 | A claim that all tumors were eradicated |
| Figure 3 | The axis and figure caption identify survival (%) | Survival cannot be relabelled as complete tumor regression |
| Text-versus-figure conflict | The narrative claims complete remission, but Figure 2 shows residual tumor growth and Figure 3 is survival | The product page must not repeat “100% complete tumor clearance” |
Example 39; Figures 2–3, PDF p59 / drawing sheet 2 of 2. The A9 corrected text still retains the conflicting wording, so the discrepancy is unresolved.
Safety and remaining uncertainty
| Topic | Current conclusion |
|---|---|
| Target-specific toxicity | No adequately characterized toxicity dataset was established for the exact patent compound in the reviewed examples |
| Clinical extrapolation | The safety of a clinical targeted nanoparticle cannot be assigned to this chemical structure without identity and formulation linkage |
| Reproducibility limits | Missing calibrated reporter units, duplicate table identifiers and the composition conflict limit cross-study comparisons |
Do not describe this lipid as nontoxic or clinically validated on the basis of the reviewed evidence.
References and source locations
- Fang W, Qin H, Xu Y, Wu Q. Amino lipid, and lipid nanoparticles and use thereof. WO2024198497A1, published October 3, 2024. Example 2; Examples 36–40; Tables 1–5; Figures 2–3.
- WO2024198497A9, corrected publication September 18, 2025. Corrected searchable text reviewed; figure and table identity not fully reverified.
- MagicRNA. ASGCT 28th Annual Meeting announcement, April 30, 2025. Sponsor-level naming of ILB-3132; not a disclosed molecular structure.
- Wang Q, et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. 2025;393:1542–1544. DOI: 10.1056/NEJMc2509522. Background platform reference only.